AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20phone%20by-%20Piotr%20Swat%20via%20Shutterstock.jpg)
Although Bristol-Myers Squibb has outperformed relative to the healthcare sector over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
President Trump's reciprocal tariffs have weakened U.S. consumer and business sentiment, as consumers grow uncertain about the 'chaotic' U.S. policy, according to Reuters.Global growth concerns have resurfaced...
/Cigna%20Group%20HQ%20phone%20-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Due to Cigna Group’s outperformance relative to its healthcare sector on a YTD basis, Wall Street analysts maintain bullish about the stock’s prospects.
/Danaher%20Corp_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Healthcare giant Danaher has significantly underperformed the broader market over the past year, yet analysts remain strongly bullish on the stock’s longer-term prospects.
Staying true to his campaign promises, President Donald Trump imposed tariffs on the United States’ largest trade partners — Mexico, Canada and China — resulting in the market reacting negatively....
The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.
During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.
Escalating geopolitical tensions and the stalling of the decline in U.S. inflation highlight defensive funds as a smart investment choice. According to Liz Ann Sonders, chief investment strategist at Charles...
This cautious stance follows a series of setbacks for AbbVie, including last month’s failure of two mid-stage trials for a schizophrenia drug.